The North America Inflammatory Bowel Disease Treatment Market would witness market growth of 6.7% CAGR during the forecast period (2021-2027).
Inflammatory bowel disease is a condition that remains for a longer period wherein a patient suffers from inflammation of the gut or digestive tract. Based on the report by the Centers for Disease Control and Prevention (CDC), in the US, around 3 million Trusted Source people are suffering from inflammatory bowel disease. Among these people, most of them had been diagnosed with the disease before they reached 30 years of age.
Moreover, the existence of strong pipeline products for treating patients suffering from inflammatory bowel disease would surge the growth of the market in the coming years. As per the report by the US National Library of Medicine, in 2019, approximately 730 clinical trials comprising observational studies, drug development, and others, were conducted for inflammatory bowel disease and among these 268 clinical trials were conducted across the US.
The inflammatory bowel disease treatment market is growing rapidly in North America. The factors contributing to the growth of the regional market are developed healthcare facilities, the presence of key players in the region, high prevalence & incidence rates of inflammatory bowel disease, and new product development and approvals. In addition to this, increased investment in research and development activities, a rise in an unhealthy lifestyle, and new pipeline products are also accountable to accelerate the market growth in the coming years.
Moreover, North America is a highly developed region, and people residing in this region are focusing on living a luxurious life. Governments in this region are also offering various reimbursement policies to the patients, which is attracting patients to go for treatments. Further, there is a huge availability of novel drugs for inflammatory bowel disease. Therefore, it is anticipated that the inflammatory bowel disease treatment market will continue growing at the fastest pace in the region.
The US market dominated the North America Retail Pharmacy Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $3003.9 million by 2027. The Canada market is experiencing a CAGR of 9.8% during (2021 - 2027). Additionally, The Mexico market would witness a CAGR of 8.9% during (2021 - 2027).
Based on Type, the market is segmented into Crohn's Disease and Ulcerative Colitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Drug Class, the market is segmented into TNF inhibitors, Anti-integrin, IL inhibitors, Corticosteroids, JAK inhibitors, Aminosalicylates and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Inflammatory Bowel Disease Treatment Market is Estimated to reach $29.2 Billion by 2027, at a CAGR of 8.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (AbbVie), Johnson & Johnson, Merck Group, Amgen, Inc., Eli Lilly and Company, Biogen, Inc., Pfizer, Inc., Novartis AG, Takeda Pharmaceutical Company Limited, and UCB S.A.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Crohn's Disease and
- Ulcerative Colitis
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Route of Administration
By Drug Class
- TNF inhibitors
- Anti-integrin
- IL inhibitors
- Corticosteroids
- JAK inhibitors
- Aminosalicylates
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Allergan PLC (AbbVie)
- Johnson & Johnson
- Merck Group
- Amgen, Inc.
- Eli Lilly and Company
- Biogen, Inc.
- Pfizer, Inc.
- Novartis AG
- Takeda Pharmaceutical Company Limited
- UCB S.A.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Inflammatory Bowel Disease Treatment Market, by Type
1.4.2 North America Inflammatory Bowel Disease Treatment Market, by Distribution Channel
1.4.3 North America Inflammatory Bowel Disease Treatment Market, by Route of Administration
1.4.4 North America Inflammatory Bowel Disease Treatment Market, by Drug Class
1.4.5 North America Inflammatory Bowel Disease Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Approvals and Trials : 2017, Aug – 2021, Sep) Leading Players
Chapter 4. North America Inflammatory Bowel Disease Treatment Market by Type
4.1 North America Crohn's Disease Market by Country
4.2 North America Ulcerative Colitis Market by Country
Chapter 5. North America Inflammatory Bowel Disease Treatment Market by Distribution Channel
5.1 North America Hospital Pharmacy Market by Country
5.2 North America Retail Pharmacy Market by Country
5.3 North America Online Pharmacy Market by Country
Chapter 6. North America Inflammatory Bowel Disease Treatment Market by Route of Administration
6.1 North America Injectable Market by Country
6.2 North America Oral Market by Country
Chapter 7. North America Inflammatory Bowel Disease Treatment Market by Drug Class
7.1 North America TNF inhibitors Market by Country
7.2 North America Anti-integrin Market by Country
7.3 North America IL inhibitors Market by Country
7.4 North America Corticosteroids Market by Country
7.5 North America JAK inhibitors Market by Country
7.6 North America Aminosalicylates Market by Country
7.7 North America Others Market by Country
Chapter 8. North America Inflammatory Bowel Disease Treatment Market by Country
8.1 US Inflammatory Bowel Disease Treatment Market
8.1.1 US Inflammatory Bowel Disease Treatment Market by Type
8.1.2 US Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.1.3 US Inflammatory Bowel Disease Treatment Market by Route of Administration
8.1.4 US Inflammatory Bowel Disease Treatment Market by Drug Class
8.2 Canada Inflammatory Bowel Disease Treatment Market
8.2.1 Canada Inflammatory Bowel Disease Treatment Market by Type
8.2.2 Canada Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.2.3 Canada Inflammatory Bowel Disease Treatment Market by Route of Administration
8.2.4 Canada Inflammatory Bowel Disease Treatment Market by Drug Class
8.3 Mexico Inflammatory Bowel Disease Treatment Market
8.3.1 Mexico Inflammatory Bowel Disease Treatment Market by Type
8.3.2 Mexico Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.3.3 Mexico Inflammatory Bowel Disease Treatment Market by Route of Administration
8.3.4 Mexico Inflammatory Bowel Disease Treatment Market by Drug Class
8.4 Rest of North America Inflammatory Bowel Disease Treatment Market
8.4.1 Rest of North America Inflammatory Bowel Disease Treatment Market by Type
8.4.2 Rest of North America Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.4.3 Rest of North America Inflammatory Bowel Disease Treatment Market by Route of Administration
8.4.4 Rest of North America Inflammatory Bowel Disease Treatment Market by Drug Class
Chapter 9. Company Profiles
9.1 Allergan PLC (AbbVie)
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Approvals and Trials:
9.2 Johnson & Johnson
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental &Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.5.2 Approvals and Trials:
9.3 Merck Group
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Acquisitions and Mergers:
9.3.5.3 Product Launches and Product Expansions:
9.4 Amgen, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expenses
9.4.5 Recent strategies and developments:
9.4.5.1 Partnerships, Collaborations, and Agreements:
9.4.5.2 Acquisitions and Mergers:
9.4.5.3 Geographical Expansions:
9.4.5.4 Approvals and Trials:
9.5 Eli Lilly and Company
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional Analysis
9.5.4 Research & Development Expense
9.6 Biogen, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Product Launches and Product Expansions:
9.6.5.3 Approvals and Trials:
9.7 Pfizer, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Acquisitions and Mergers:
9.7.5.2 Approvals and Trials:
9.8 Novartis AG
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Acquisitions and Mergers:
9.8.5.3 Approvals and Trials:
9.9 Takeda Pharmaceutical Company Limited
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Partnerships, Collaborations, and Agreements:
9.9.5.2 Acquisitions and Mergers:
9.9.5.3 Product Launches and Product Expansions:
9.9.5.4 Approvals and Trials:
9.10. UCB S.A.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Regional Analysis
9.10.4 Research & Development Expense
9.10.5 Recent strategies and developments:
9.10.5.1 Partnerships, Collaborations, and Agreements:
9.10.5.2 Approvals and Trials:
TABLE 1 North America Inflammatory Bowel Disease Treatment Market, 2017 - 2020, USD Million
TABLE 2 North America Inflammatory Bowel Disease Treatment Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Inflammatory Bowel Disease Treatment Market
TABLE 4 Product Launches And Product Expansions– Inflammatory Bowel Disease Treatment Market
TABLE 5 Acquisition and Mergers– Inflammatory Bowel Disease Treatment Market
TABLE 6 Geographical Expansions– Inflammatory Bowel Disease Treatment Market
TABLE 7 Approvals and TRials– Inflammatory Bowel Disease Treatment Market
TABLE 8 North America Inflammatory Bowel Disease Treatment Market by Type, 2017 - 2020, USD Million
TABLE 9 North America Inflammatory Bowel Disease Treatment Market by Type, 2021 - 2027, USD Million
TABLE 10 North America Crohn's Disease Market by Country, 2017 - 2020, USD Million
TABLE 11 North America Crohn's Disease Market by Country, 2021 - 2027, USD Million
TABLE 12 North America Ulcerative Colitis Market by Country, 2017 - 2020, USD Million
TABLE 13 North America Ulcerative Colitis Market by Country, 2021 - 2027, USD Million
TABLE 14 North America Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 15 North America Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 16 North America Hospital Pharmacy Market by Country, 2017 - 2020, USD Million
TABLE 17 North America Hospital Pharmacy Market by Country, 2021 - 2027, USD Million
TABLE 18 North America Retail Pharmacy Market by Country, 2017 - 2020, USD Million
TABLE 19 North America Retail Pharmacy Market by Country, 2021 - 2027, USD Million
TABLE 20 North America Online Pharmacy Market by Country, 2017 - 2020, USD Million
TABLE 21 North America Online Pharmacy Market by Country, 2021 - 2027, USD Million
TABLE 22 North America Inflammatory Bowel Disease Treatment Market by Route of Administration, 2017 - 2020, USD Million
TABLE 23 North America Inflammatory Bowel Disease Treatment Market by Route of Administration, 2021 - 2027, USD Million
TABLE 24 North America Injectable Market by Country, 2017 - 2020, USD Million
TABLE 25 North America Injectable Market by Country, 2021 - 2027, USD Million
TABLE 26 North America Oral Market by Country, 2017 - 2020, USD Million
TABLE 27 North America Oral Market by Country, 2021 - 2027, USD Million
TABLE 28 North America Inflammatory Bowel Disease Treatment Market by Drug Class, 2017 - 2020, USD Million
TABLE 29 North America Inflammatory Bowel Disease Treatment Market by Drug Class, 2021 - 2027, USD Million
TABLE 30 North America TNF inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 31 North America TNF inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 32 North America Anti-integrin Market by Country, 2017 - 2020, USD Million
TABLE 33 North America Anti-integrin Market by Country, 2021 - 2027, USD Million
TABLE 34 North America IL inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 35 North America IL inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 36 North America Corticosteroids Market by Country, 2017 - 2020, USD Million
TABLE 37 North America Corticosteroids Market by Country, 2021 - 2027, USD Million
TABLE 38 North America JAK inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 39 North America JAK inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 40 North America Aminosalicylates Market by Country, 2017 - 2020, USD Million
TABLE 41 North America Aminosalicylates Market by Country, 2021 - 2027, USD Million
TABLE 42 North America Others Market by Country, 2017 - 2020, USD Million
TABLE 43 North America Others Market by Country, 2021 - 2027, USD Million
TABLE 44 North America Inflammatory Bowel Disease Treatment Market by Country, 2017 - 2020, USD Million
TABLE 45 North America Inflammatory Bowel Disease Treatment Market by Country, 2021 - 2027, USD Million
TABLE 46 US Inflammatory Bowel Disease Treatment Market, 2017 - 2020, USD Million
TABLE 47 US Inflammatory Bowel Disease Treatment Market, 2021 - 2027, USD Million
TABLE 48 US Inflammatory Bowel Disease Treatment Market by Type, 2017 - 2020, USD Million
TABLE 49 US Inflammatory Bowel Disease Treatment Market by Type, 2021 - 2027, USD Million
TABLE 50 US Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 51 US Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 52 US Inflammatory Bowel Disease Treatment Market by Route of Administration, 2017 - 2020, USD Million
TABLE 53 US Inflammatory Bowel Disease Treatment Market by Route of Administration, 2021 - 2027, USD Million
TABLE 54 US Inflammatory Bowel Disease Treatment Market by Drug Class, 2017 - 2020, USD Million
TABLE 55 US Inflammatory Bowel Disease Treatment Market by Drug Class, 2021 - 2027, USD Million
TABLE 56 Canada Inflammatory Bowel Disease Treatment Market, 2017 - 2020, USD Million
TABLE 57 Canada Inflammatory Bowel Disease Treatment Market, 2021 - 2027, USD Million
TABLE 58 Canada Inflammatory Bowel Disease Treatment Market by Type, 2017 - 2020, USD Million
TABLE 59 Canada Inflammatory Bowel Disease Treatment Market by Type, 2021 - 2027, USD Million
TABLE 60 Canada Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 61 Canada Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 62 Canada Inflammatory Bowel Disease Treatment Market by Route of Administration, 2017 - 2020, USD Million
TABLE 63 Canada Inflammatory Bowel Disease Treatment Market by Route of Administration, 2021 - 2027, USD Million
TABLE 64 Canada Inflammatory Bowel Disease Treatment Market by Drug Class, 2017 - 2020, USD Million
TABLE 65 Canada Inflammatory Bowel Disease Treatment Market by Drug Class, 2021 - 2027, USD Million
TABLE 66 Mexico Inflammatory Bowel Disease Treatment Market, 2017 - 2020, USD Million
TABLE 67 Mexico Inflammatory Bowel Disease Treatment Market, 2021 - 2027, USD Million
TABLE 68 Mexico Inflammatory Bowel Disease Treatment Market by Type, 2017 - 2020, USD Million
TABLE 69 Mexico Inflammatory Bowel Disease Treatment Market by Type, 2021 - 2027, USD Million
TABLE 70 Mexico Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 71 Mexico Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 72 Mexico Inflammatory Bowel Disease Treatment Market by Route of Administration, 2017 - 2020, USD Million
TABLE 73 Mexico Inflammatory Bowel Disease Treatment Market by Route of Administration, 2021 - 2027, USD Million
TABLE 74 Mexico Inflammatory Bowel Disease Treatment Market by Drug Class, 2017 - 2020, USD Million
TABLE 75 Mexico Inflammatory Bowel Disease Treatment Market by Drug Class, 2021 - 2027, USD Million
TABLE 76 Rest of North America Inflammatory Bowel Disease Treatment Market, 2017 - 2020, USD Million
TABLE 77 Rest of North America Inflammatory Bowel Disease Treatment Market, 2021 - 2027, USD Million
TABLE 78 Rest of North America Inflammatory Bowel Disease Treatment Market by Type, 2017 - 2020, USD Million
TABLE 79 Rest of North America Inflammatory Bowel Disease Treatment Market by Type, 2021 - 2027, USD Million
TABLE 80 Rest of North America Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 81 Rest of North America Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 82 Rest of North America Inflammatory Bowel Disease Treatment Market by Route of Administration, 2017 - 2020, USD Million
TABLE 83 Rest of North America Inflammatory Bowel Disease Treatment Market by Route of Administration, 2021 - 2027, USD Million
TABLE 84 Rest of North America Inflammatory Bowel Disease Treatment Market by Drug Class, 2017 - 2020, USD Million
TABLE 85 Rest of North America Inflammatory Bowel Disease Treatment Market by Drug Class, 2021 - 2027, USD Million
TABLE 86 Key Information – Allergan PLC
TABLE 87 Key information –Johnson & Johnson
TABLE 88 key Information – Merck Group
TABLE 89 Key Information – Amgen, Inc.
TABLE 90 Key Information – Eli Lilly and Company
TABLE 91 Key Information – Biogen, Inc.
TABLE 92 Key Information – Pfizer, Inc.
TABLE 93 Key Information – Novartis AG
TABLE 94 Key Information – Takeda Pharmaceutical Company Limited
TABLE 95 Key Information – UCB S.A.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 4 Key Strategic Move: (Approvals and Trials : 2017, Aug – 2021, Sep) Leading Players
FIG 5 Recent strategies and developments: Merck Group
FIG 6 Recent strategies and developments: Amgen, Inc.
FIG 7 Recent strategies and developments: Biogen, Inc.
FIG 8 Recent strategies and developments: Pfizer, Inc.
FIG 9 Recent strategies and developments: Novartis AG
FIG 10 Recent strategies and developments: Takeda Pharmaceutical Company Limited